Anika Therapeutics, Inc. (ANIK) P/E Ratio History
Historical price-to-earnings valuation from 1997 to 2021
Loading P/E history...
ANIK Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 8, 2026, Anika Therapeutics, Inc. (ANIK) trades at a price-to-earnings ratio of -19.9x, with a stock price of $15.14 and trailing twelve-month earnings per share of $-0.82.
The current P/E is 167% below its 5-year average of 29.9x. Over the past five years, ANIK's P/E has ranged from a low of 14.5x to a high of 123.6x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.3x, ANIK trades at a 189% discount to its sector peers. The sector includes 241 companies with P/E ratios ranging from 0.0x to 177.5x.
Relative to the broader market, ANIK trades at a notable discount to the S&P 500 median P/E of 25.1x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our ANIK DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
ANIK P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $548M | 11.5Lowest | - | +14% | |
| $6B | 26.7 | - | -22% | |
| $8B | 25.5 | 1.11 | -25% | |
| $12B | 29.8 | - | +1% | |
| $12B | 21.7 | 0.70Best | +423%Best |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
ANIK Historical P/E Data (1997–2021)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2021 Q4 | Fri Dec 31 2021 00:00:00 GM | $35.83 | $0.29 | 123.6x | +376% |
| FY2020 Q2 | $37.73 | $0.78 | 48.4x | +86% | |
| FY2020 Q1 | $28.91 | $1.99 | 14.5x | -44% | |
| FY2019 Q4 | $51.85 | $1.90 | 27.3x | +5% | |
| FY2019 Q3 | Mon Sep 30 2019 00:00:00 GM | $54.89 | $2.16 | 25.4x | -2% |
| FY2019 Q2 | Sun Jun 30 2019 00:00:00 GM | $40.62 | $2.05 | 19.8x | -24% |
| FY2019 Q1 | Sun Mar 31 2019 00:00:00 GM | $30.24 | $2.06 | 14.7x | -43% |
| FY2018 Q4 | Mon Dec 31 2018 00:00:00 GM | $33.61 | $1.29 | 26.1x | +0% |
| FY2018 Q3 | Sun Sep 30 2018 00:00:00 GM | $42.18 | $1.28 | 33.0x | +27% |
| FY2018 Q2 | Sat Jun 30 2018 00:00:00 GM | $32.00 | $1.21 | 26.4x | +2% |
| FY2018 Q1 | Sat Mar 31 2018 00:00:00 GM | $49.72 | $1.29 | 38.5x | +48% |
| FY2017 Q4 | Sun Dec 31 2017 00:00:00 GM | $53.91 | $2.12 | 25.4x | -2% |
Average P/E for displayed period: 26.0x
See ANIK's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ANIK Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare ANIK vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonANIK — Frequently Asked Questions
Quick answers to the most common questions about buying ANIK stock.
Is ANIK stock overvalued or undervalued?
ANIK trades at -19.9x P/E, below its 5-year average of 29.9x. At the N/A percentile of historical range, the stock is priced at a discount to its own history.
How does ANIK's valuation compare to peers?
Anika Therapeutics, Inc. P/E of -19.9x compares to sector median of 22.3x. The discount suggests lower growth expectations or higher risk.
What is ANIK's PEG ratio?
ANIK PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 1997-2021.